糜蛋白酶治疗慢性阻塞性肺疾病疗效的Meta分析

Analysis of chymotrypsin for chronic obstructive pulmonary disease:a meta analysis

目的系统评价糜蛋白酶治疗慢性阻塞性肺疾病(COPD)的疗效。方法检索中国知网数据库、万方数据库和维普数据库,搜索糜蛋白酶治疗COPD的文献,对纳入的研究进行Meta分析。结果共纳入6篇文献537例患者。Meta分析结果显示,含糜蛋白酶的治疗组的临床疗效、住院时间、动脉血氧分压(Pa O2)、喘憋消失时间均优于对照组;亚组分析中,常规治疗与糜蛋白酶的比较,以及氨溴索与氨溴索联合糜蛋白酶的比较差异均有统计学意义。结论糜蛋白酶可以有效治疗COPD。

Objective To systematically evaluate the clinical efficacy of chymotrypsin for chronic obstructive pulmonary disease(COPD).Methods The full text of clinical efficacy involving chymotrypsin for COPD was retrieved from CNKI,Wanfang database,VIP database,the quality of the included studies and extracted data were evaluated,and Revman 5.0 was adopted for meta analysis.Results 537 patients were included in 6 studies,and the eligibility criteria were finally met.The meta analysis suggested that there was significant difference between treatment group and control group in clinical efficacy,hospital stay,Pa0_(2) and time of wheezing disappearance was better than those in control group.In subgroup analysis,there were significant differences between conventional therapy and chymotrypsin,and between ambroxol and ambroxol combined chymotrypsin.Conclusion Chymotrypsin can effectively treat chronic obstructive pulmonary disease.